马平, 孙乔, 赵希畅, 曹志钦, 王涛, 辛辛, 张鹏, 张枭, 金樱枝, 瞿镇宇, 付文婕, 陈盼盼, 裴启星. 上海市浦东新区2014—2015年HIV-1感染者治疗前基因特性及耐药分析[J]. 上海预防医学, 2016, 28(12): 839-842,847.
引用本文: 马平, 孙乔, 赵希畅, 曹志钦, 王涛, 辛辛, 张鹏, 张枭, 金樱枝, 瞿镇宇, 付文婕, 陈盼盼, 裴启星. 上海市浦东新区2014—2015年HIV-1感染者治疗前基因特性及耐药分析[J]. 上海预防医学, 2016, 28(12): 839-842,847.
shu
MA Ping, SUN Qiao, ZHAO Xi-chang, CAO Zhi-qin, WANG Tao, XIN Xin, ZHANG Peng, ZHANG Xiao, JINYing-zhi, QU Zhen-yu, FU Wen-jie, CHEN Pan-pan, PEI Qi-xing. Analysis of HIV-1 genetic features and drug resistance background for HIV-1-infected individuals living in Pudong New Area of Shanghai before antiretroviral treatment from 2014 to 2015[J]. Shanghai Journal of Preventive Medicine, 2016, 28(12): 839-842,847.
Citation: MA Ping, SUN Qiao, ZHAO Xi-chang, CAO Zhi-qin, WANG Tao, XIN Xin, ZHANG Peng, ZHANG Xiao, JINYing-zhi, QU Zhen-yu, FU Wen-jie, CHEN Pan-pan, PEI Qi-xing. Analysis of HIV-1 genetic features and drug resistance background for HIV-1-infected individuals living in Pudong New Area of Shanghai before antiretroviral treatment from 2014 to 2015[J]. Shanghai Journal of Preventive Medicine, 2016, 28(12): 839-842,847.
shu

上海市浦东新区2014—2015年HIV-1感染者治疗前基因特性及耐药分析

Analysis of HIV-1 genetic features and drug resistance background for HIV-1-infected individuals living in Pudong New Area of Shanghai before antiretroviral treatment from 2014 to 2015

    摘要
  • 摘要: 目的 了解上海市浦东新区2014—2015年进入治疗的HIV-1感染者的基因特性及耐药情况。方法 以巢式RT-PCR方法扩增91份治疗前HIV-1感染者样品HIV-1聚合酶片段，测序，构建进化树并进行HIV-1基因亚型分析，将获得的核酸序列提交至斯坦福大学HIV耐药数据库进行耐药位点分析。结果 91份样品测序成功53份，其中CRF01_AE重组体占67.9%（36/53），B亚型占7.5%（4/53），C亚型占3.8%（2/53），CRF07_BC重组体占20.8%（11/53）。在53条基因序列中41条检测到与HIV-1蛋白酶抑制剂（PIs）和逆转录酶抑制剂（RTIs）相关的共计66个突变位点，其中4个耐药突变位点与非核苷类逆转录酶抑制剂（NNRTIs）及核苷类逆转录酶抑制剂（NRTIs）耐药相关，原发耐药率为7.5%（4/53）；37条基因序列检测到的62个突变位点与HIV-1 PIs和RTIs继发耐药性突变或基因的多形态改变相关。结论 2014—2015年进入治疗的HIV-1感染者基因多种亚型并存，以CRF01_AE重组体为主。对基因序列发生的原发和继发耐药性突变应引起重视。

     

    Abstract: Objective To understand the genetic features and drug resistance of HIV-1 infected individuals living in Pudong New Area of Shanghai before antiretroviral therapy from 2014 to 2015. Methods A total of 91 plasma samples of HIV-1 infected individuals before antiretroviral therapy were collected; HIV-1 pol gene were amplified by nest RT-PCR, and were sequenced and phylogenetically analyzed. Drug resistance associated mutations in protease and reverse transcriptase regions were analyzed with Stanford University HIV/AIDS Drug Resistance Database. Results Among the 91 plasma samples, a total of 53 samples were sequenced, among which CRF01_AE stood at 67.9%(36/53), subtype B stood at 7.5%(4/53), subtype C stood at 3.8%(2/53), CRF07_BC stood at 20.8%(11/53) were detected. 66 mutations conferring primary and secondary resistance polymorphic to protease inhibitors (PIs) and to reverse transcriptase (RTIs) were detected in 41 of 53 patients, and 4 mutations conferring primary resistance to RTIs were detected in 4 of 53 patients(7.5%); 62 mutations conferring secondary resistance and polymorphic to PIs and to RTIs were detected in 37 of 53 patients. Conclusion There is genetic subtype diversity of HIV-1 infected individuals before antiretroviral therapy from 2014 to 2015, among which CRF01_AE takes the most. More attention should be paid to primary and secondary drug resistance mutations in gene sequence.

     

    • HTML全文
    • 参考文献(9)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回